Celularity Inc (CELU) - Total Assets
Based on the latest financial reports, Celularity Inc (CELU) holds total assets worth $114.24 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Celularity Inc (CELU) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Celularity Inc - Total Assets Trend (2018–2024)
This chart illustrates how Celularity Inc's total assets have evolved over time, based on quarterly financial data. Explore Celularity Inc (CELU) investment intensity to see how much of total assets are deployed in long-term investments.
Celularity Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Celularity Inc's total assets of $114.24 Million consist of 15.5% current assets and 84.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.6% |
| Accounts Receivable | $13.56 Million | 10.2% |
| Inventory | $5.41 Million | 4.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.25 Million | 7.0% |
| Goodwill | $7.35 Million | 5.5% |
Asset Composition Trend (2018–2024)
This chart illustrates how Celularity Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Celularity Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celularity Inc's current assets represent 15.5% of total assets in 2024, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2024, down from 100.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 2122289.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
Celularity Inc Competitors by Total Assets
Key competitors of Celularity Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Celularity Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.16 | 0.19 | 2.70 |
| Quick Ratio | 0.12 | 0.14 | 2.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-54.72 Million | $-61.67 Million | $45.48 Million |
Celularity Inc - Advanced Valuation Insights
This section examines the relationship between Celularity Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.89 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -7.8% |
| Total Assets | $132.68 Million |
| Market Capitalization | $22.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Celularity Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Celularity Inc's assets decreased by 7.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Celularity Inc (2018–2024)
The table below shows the annual total assets of Celularity Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $132.68 Million | -7.79% |
| 2023-12-31 | $143.89 Million | -64.12% |
| 2022-12-31 | $401.07 Million | -3.15% |
| 2021-12-31 | $414.13 Million | -3.92% |
| 2020-12-31 | $431.01 Million | -17.35% |
| 2019-12-31 | $521.50 Million | +2110617.61% |
| 2018-12-31 | $24.71K | -- |
About Celularity Inc
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioB… Read more